Catalyst Event
Johnson & Johnson (JNJ) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
5/31/2026, 12:00:00 AM
On May 31, 2026, Johnson & Johnson announced positive final results from the Phase 3 PROTEUS study of ERLEADA in prostate cancer; successful Phase 3 results for an oncology blockbuster typically drive a 5-10% price impact, expected.
Korean Translation
2026년 5월 31일, Johnson & Johnson은 ERLEADA의 3상 PROTEUS 연구에서 긍정적인 최종 결과를 발표함. 항암제 블록버스터의 성공적인 3상 결과는 5-10%의 주가 상승을 견인할 것으로 예상됨.
Related Recent Events
ON Semiconductor Corp (ON) · Other
Financial Analyst Day in New York City to provide updates on strategy and long-term financial plans is scheduled. Impact estimated at >=1% as analyst days usually provide incremental updates; the event is scheduled.
9/16/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart's Q2 FY2027 earnings release is scheduled.
8/20/2026, 12:00:00 AM
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Constellation Energy Corp (CEG) · Earnings Release
Q2 2026 earnings release on August 6, 2026, with low importance estimated based on historical price movements, is expected.
8/6/2026, 12:00:00 AM